A multinational healthcare company and a front runner in epigenetic research has developed a non-invasive urine test (“liquid biopsy”) that measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1) to help Physicians determine at what level a patient is at risk for prostate cancer, potentially avoiding intrusive biopsies for some. With approximately 1 million men receiving an inconclusive biopsy result each year in the US, this diagnostic solution would address a significant unmet medical need for timely, actionable information that can aid in the reduction of unnecessary repeat biopsies.
To further enhance their prostate cancer test, the company needed to compare its product against biopsied tissues. But the logistics of identifying 2,000 patients and collecting tissues at 21 US urology centers within 6 months was daunting.
"I worked with this Sponsor as a consultant to design and implement a clinical utility study with their prostate cancer detection assay. My experience with Catalyst was first-rate and I would work with them again."